Slideshow
Author(s):
Two new studies shed light on risk factors for stroke and MI, and a third suggests neurologic use s for Zolpidem that don’t involve treating insomnia.
FDA Action Update, September 2024: Approvals, Designations, and Clearances
Episode 109: AB126, Exosomes, and Cerebroprotection for Stroke
NeurologyLive® Brain Games: September 29, 2024
Episode 105: Recapping Conversations in Neurology From 2023
FDA Grants Breakthrough Therapy Designation to Edaravone Dexborneol Combination Therapy for Acute Ischemic Stroke
Patient Dosing Underway for Phase 2 Study of RNA Aptamer BB-031 in Acute Ischemic Stroke